ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

As previously disclosed, Mr. David (Xiaoying) Gao resigned from his posts in the Audit Committee, the Compensation Committee and the Governance and Nominating Committee of the board of directors (the "Board") of China Biologic Products, Inc. (the "Company"), in connection with his assumption of the position of the Chief Executive Officer of the Company. In order to fill the vacancies in these Committees, the Board has elected Ms. Sandy (Han) Zhang, an independent director, to be a member of the Audit Committee, Prof. Wenfang Liu, an independent director, to be a member of the Compensation Committee, and Mr. Zhijun Tong, an independent director, to be a member of the Governance and Nominating Committee, effective on May 20, 2012. The Board has also elected Mr. Sean Shao, a current member of the Compensation Committee, to be the Chair of the Compensation Committee, effective on May 20, 2012. The Board has determined that Ms. Zhang meets NASDAQ's financial sophistication requirements.

There is no family relationship between each of Ms. Zhang, Mr. Tong, Prof. Liu and Mr. Shao and any other directors or executive officers of the Company. In addition, there has been no transaction, nor is there any currently proposed transaction, between each of Ms. Zhang, Mr. Tong, Prof. Liu and Mr. Shao and the Company that would require disclosure under Item 404(a) of Regulation S-K.

---